Lincoln Property Company and MetLife Investment Management announced that 300 Third Ave., a 143,533-square-foot, purpose-built life science development in Waltham, MA, is fully leased to two biotechnology tenants: Biocytogen and BPG Bio. A global biotechnology company, Biocytogen expanded its footprint with a new 35,000-square-foot, full-floor lease. The company established its U.S. headquarters at 300 Third in 2022 and will now occupy more than 70,000 square feet.
“Lincoln is proud to partner with both Biocytogen and BPG Bio as they grow at 300 Third,” said Scott Faber, SVP at Lincoln. “300 Third was expertly designed for best-in-class life science clients and we are honored to have that recognized with a fully leased building.”
Lincoln’s Tim Latham, Christopher Scott and Chris Devaux represented ownership. Colliers SVP Tim Allen represented Biocytogen in the expansion and extension. Owned by clients of MetLife Investment Management, 300 Third is located in the Route 128 life sciences cluster.
The post Biocytogen Expands, Bringing Waltham Life Sciences Building to 100% Occupancy appeared first on Connect CRE.
